Navigation Links
Screening detects ovarian cancer using neighboring cells
Date:4/22/2013

Pioneering biophotonics technology developed at Northwestern University is the first screening method to detect the early presence of ovarian cancer in humans by examining cells easily brushed from the neighboring cervix or uterus, not the ovaries themselves.

A research team from Northwestern and NorthShore University HealthSystem (NorthShore) conducted an ovarian cancer clinical study at NorthShore. Using partial wave spectroscopic (PWS) microscopy, they saw diagnostic changes in cells taken from the cervix or uterus of patients with ovarian cancer even though the cells looked normal under a microscope.

The results have the potential to translate into a minimally invasive early detection method using cells collected by a swab, exactly like a Pap smear. No reliable early detection method for ovarian cancer currently exists.

In previous Northwestern-NorthShore studies, the PWS technique has shown promising results in the early detection of colon, pancreatic and lung cancers using cells from neighboring organs. If commercialized, PWS could be in clinical use for one or more cancers in approximately five years.

The ovarian cancer study was published this month by the International Journal of Cancer.

PWS uses light scattering to examine the architecture of cells at the nanoscale and can detect profound changes that are the earliest known signs of carcinogenesis. These changes can be seen in cells far from the tumor site or even before a tumor forms.

"We were surprised to discover we could see diagnostic changes in cells taken from the endocervix in patients who had ovarian cancer," said Vadim Backman, who developed PWS at Northwestern. "The advantage of nanocytology -- and why we are so excited about it -- is we don't need to wait for a tumor to develop to detect cancer."

Backman is a professor of biomedical engineering at the McCormick School of Engineering and Applied Science. He and his longtime collaborator, Hemant K. Roy, M.D., formerly of NorthShore, have been working together for more than a decade and conducting clinical trials of PWS at NorthShore for four years. Backman and Roy both are authors of the paper.

"The changes we have seen in cells have been identical, no matter which organ we are studying," Backman said. "We have stumbled upon a universal cell physiology that can help us detect difficult cancers early. If the changes are so universal, they must be very important."

Ovarian cancer, which ranks fifth in cancer fatalities among American women, usually goes undetected until it has spread elsewhere. The cancer is difficult to treat at this late stage and often is fatal.

"This intriguing finding may represent a breakthrough that would allow personalization of screening strategies for ovarian cancer via a minimally intrusive test that could be coupled to the Pap smear," Roy said.

At the time of the ovarian cancer study, Roy was director of gastroenterology research at NorthShore and worked with Jean A. Hurteau, M.D., a gynecological oncologist at NorthShore. (Hurteau is an author of the paper.) Roy is now chief of the section of gastroenterology at Boston University School of Medicine and Boston Medical Center.

The study included a total of 26 individuals. For cells taken from the endometrium (part of the uterus), there were 26 patients (11 with ovarian cancer and 15 controls); for cells taken from the endocervix, there were 23 patients (10 with ovarian cancer and 13 controls). The small size of the study reflects the difficulty in recruiting ovarian cancer patients.

Cells were placed on slides and then examined using PWS. The results showed a significant increase in the disorder of the nanoarchitecture of epithelial cells obtained from cancer patients compared to controls for both the endometrium and endocervix studies.

The cells for the ovarian cancer study were taken from the cervix and uterus. For the earlier lung cancer study, cells were brushed from the cheek. For the colon, cells came from the rectum, and for the pancreas, cells came from the duodenum. Cells from these neighboring organs showed changes at the nanoscale when cancer was present.

PWS can detect cell features as small as 20 nanometers, uncovering differences in cells that appear normal using standard microscopy techniques. PWS measures the disorder strength of the nanoscale organization of the cell, which is a strong marker for the presence of cancer in the organ or in a nearby organ.

The PWS-based test makes use of the "field effect," a biological phenomenon in which cells located some distance from the malignant or pre-malignant tumor undergo molecular and other changes.


'/>"/>

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University
Source:Eurekalert

Related medicine news :

1. Gulfside Dental Hosts Successful Oral Cancer Screening Event in honor of National Oral Cancer Awareness Month
2. 2 views are better than 1 in 3-D breast screening
3. Screening breast ultrasound detects cancers missed on mammography in women with dense breasts
4. ACMG releases statement on noninvasive prenatal screening
5. For breast cancer screening, 1 size doesnt fit all
6. Penn Study finds virtual colonoscopy is used appropriately, may expand screening to more patients
7. Moffitt Cancer Center researchers discuss new frontiers in breast cancer screening
8. Don’t Cease Background Screenings or Hire Unqualified Ex-Cons Because of New EEOC Directive, Says iReviewNow and SecurTest
9. Study examines outcomes of screening mammography for age, breast density, hormone therapy
10. CDC and AGA join forces to bring colorectal cancer screening to the uninsured
11. Digital rectal exam remains important part of prostate screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology: